Boxer Capital, LLC - 10 May 2024 Form 4 Insider Report for iTeos Therapeutics, Inc. (ITOS)

Reporting relationship: Other*
Issuer ticker: ITOS
Reported as of: 10 May 2024
Net transaction value: +$19,999,998
SEC form: 4
Accepted by SEC: 14 May 2024, 21:32:26 UTC
Prior SEC filing: 08 Feb 2024
Source filing: View source filing
Reporting owner signature: /s/ Aaron I. Davis, Chief Executive Officer, Boxer Capital, LLC

Key filing fact

Boxer Capital, LLC filed Form 4 for iTeos Therapeutics, Inc. (ITOS) on 14 May 2024.

Key facts

This page summarizes Boxer Capital, LLC's Form 4 filing for iTeos Therapeutics, Inc. (ITOS).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 14 May 2024, 21:32.

Change

Previous filing in this sequence was filed on 08 Feb 2024.
Current net transaction value: +$19,999,998.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ITOS transaction

Common Stock

Award

Transaction value: $19,999,998
Shares: +1,142,857
Change %: +63%
Price: $17.50
Shares after: 2,946,915
Date: 10 May 2024
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Asset Management Inc. Mr. Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.

SEC remarks

Aaron Davis, the CEO of Boxer Capital, LLC, is a director of Iteos Therapeutics, Inc. (the "Issuer"). The reporting persons other than Mr. Davis previously reported ceasing to be subject to Section 16 of the Exchange Act with respect to the Issuer. This filing is being made by those other reporting persons without conceding that they are subject to Section 16 of the Exchange Act with respect to the Issuer.